Compare Stocks → Exposed: 10 CENT Crypto to Explode April 20th? (From True Market Insiders) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:ANNXNASDAQ:ATOSNASDAQ:NVCTNASDAQ:OBSVNASDAQ:PIRS Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeANNXAnnexon$4.45+0.2%$5.71$1.57▼$8.40$400.63M1.141.52 million shs3.33 million shsATOSAtossa Therapeutics$1.50+0.7%$1.41$0.59▼$2.31$187.95M1.21.40 million shs1.85 million shsNVCTNuvectis Pharma$6.71+1.8%$8.43$6.20▼$18.65$119.24M0.2897,214 shs50,696 shsOBSVObsEva$0.01$0.02$0.08▼$2.14$390K0.688.94 million shs8,190 shsPIRSPieris Pharmaceuticals$11.93-0.6%$13.87$10.89▼$80.80$1.18B0.489,247 shs39,950 shs10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceANNXAnnexon-2.31%-13.20%-34.71%0.00%-21.97%ATOSAtossa Therapeutics+4.93%-3.25%-10.78%+84.18%+121.73%NVCTNuvectis Pharma-7.18%-5.59%-26.94%-13.18%-54.04%OBSVObsEva0.00%+1,150.00%-60.00%-90.00%-94.05%PIRSPieris Pharmaceuticals+3.01%-8.23%-24.75%-5.88%-82.70%Exposed: 10 CENT Crypto to Explode April 20th? (Ad)Former Wall Street Insider and Professional Money Manager Reveals 4 Cryptos BETTER Than BitcoinClick For My #1 FREE Crypto for 2024MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationANNXAnnexon3.2984 of 5 stars4.53.00.00.01.72.50.6ATOSAtossa Therapeutics1.0942 of 5 stars3.51.00.00.02.01.70.0NVCTNuvectis Pharma2.5856 of 5 stars3.51.00.00.03.05.00.0OBSVObsEvaN/AN/AN/AN/AN/AN/AN/AN/APIRSPieris Pharmaceuticals0.5141 of 5 stars0.03.00.04.61.50.80.0Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceANNXAnnexon3.00Buy$14.43224.24% UpsideATOSAtossa Therapeutics3.00Buy$4.50200.00% UpsideNVCTNuvectis Pharma3.00Buy$21.00212.97% UpsideOBSVObsEvaN/AN/AN/AN/APIRSPieris Pharmaceuticals2.00HoldN/AN/ACurrent Analyst RatingsLatest ANNX, ATOS, OBSV, NVCT, and PIRS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/24/2024ANNXAnnexonCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight4/16/2024ATOSAtossa TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$4.004/11/2024ANNXAnnexonNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$16.004/3/2024ANNXAnnexonCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight4/2/2024ATOSAtossa TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$4.004/1/2024ANNXAnnexonJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$11.00 ➝ $13.003/28/2024ANNXAnnexonBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$7.00 ➝ $10.003/27/2024ANNXAnnexonWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$11.00 ➝ $12.003/27/2024ANNXAnnexonHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$30.003/27/2024ANNXAnnexonNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$16.003/4/2024ANNXAnnexonHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$30.00(Data available from 4/24/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookANNXAnnexonN/AN/AN/AN/A$3.20 per shareN/AATOSAtossa TherapeuticsN/AN/AN/AN/A$0.73 per shareN/ANVCTNuvectis PharmaN/AN/AN/AN/A$0.70 per shareN/AOBSVObsEva$20.11M0.02N/AN/A$0.41 per share0.01PIRSPieris Pharmaceuticals$42.81M27.57N/AN/A$0.27 per share44.19Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateANNXAnnexon-$134.24M-$1.78N/AN/AN/AN/A-66.54%-53.52%5/13/2024 (Estimated)ATOSAtossa Therapeutics-$30.09M-$0.24N/AN/AN/AN/A-31.01%-29.77%5/20/2024 (Estimated)NVCTNuvectis Pharma-$22.26M-$1.43N/AN/AN/AN/A-144.80%-107.80%5/8/2024 (Estimated)OBSVObsEva-$58.38M-$0.92N/A∞N/AN/A-416.36%-92.01%N/APIRSPieris Pharmaceuticals-$24.54M-$0.28N/AN/AN/A-57.33%-90.17%-38.12%5/8/2024 (Estimated)Latest ANNX, ATOS, OBSV, NVCT, and PIRS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails4/1/2024Q4 2023ATOSAtossa TherapeuticsN/A-$0.06-$0.06-$0.06N/AN/A3/29/2024Q4 2023PIRSPieris PharmaceuticalsN/A-$4.00-$4.00-$0.06N/A$1.30 million3/26/2024Q4 2023ANNXAnnexon-$0.45-$0.36+$0.09-$0.36N/AN/A3/5/2024Q4 2023NVCTNuvectis Pharma-$0.40-$0.41-$0.01-$0.41N/AN/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthANNXAnnexonN/AN/AN/AN/AN/AATOSAtossa TherapeuticsN/AN/AN/AN/AN/ANVCTNuvectis PharmaN/AN/AN/AN/AN/AOBSVObsEvaN/AN/AN/AN/AN/APIRSPieris PharmaceuticalsN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioANNXAnnexonN/A14.7214.72ATOSAtossa TherapeuticsN/A17.6117.61NVCTNuvectis PharmaN/A2.752.75OBSVObsEvaN/A0.610.61PIRSPieris PharmaceuticalsN/A3.243.24OwnershipInstitutional OwnershipCompanyInstitutional OwnershipANNXAnnexonN/AATOSAtossa Therapeutics12.74%NVCTNuvectis Pharma96.77%OBSVObsEva17.52%PIRSPieris Pharmaceuticals40.11%Insider OwnershipCompanyInsider OwnershipANNXAnnexon19.11%ATOSAtossa Therapeutics7.80%NVCTNuvectis Pharma38.85%OBSVObsEva14.40%PIRSPieris Pharmaceuticals8.89%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableANNXAnnexon7190.03 million72.82 millionOptionableATOSAtossa Therapeutics12125.30 million115.53 millionOptionableNVCTNuvectis Pharma1317.77 million10.87 millionNot OptionableOBSVObsEva4877.97 million66.74 millionNot OptionablePIRSPieris Pharmaceuticals4698.93 million90.14 millionOptionableANNX, ATOS, OBSV, NVCT, and PIRS HeadlinesSourceHeadlinePieris Pharmaceuticals (NASDAQ:PIRS) Shares Gap Down to $12.00marketbeat.com - April 24 at 3:35 PMPieris Pharmaceuticals (NASDAQ:PIRS) Sees Large Volume Increasemarketbeat.com - April 23 at 12:31 PMPieris Pharmaceuticals (NASDAQ:PIRS) Earns Hold Rating from Analysts at StockNews.comamericanbankingnews.com - April 21 at 2:14 AMPieris Pharmaceuticals Stock Scheduled to Reverse Split on Tuesday, April 23rd (NASDAQ:PIRS)americanbankingnews.com - April 21 at 1:24 AMPieris Pharmaceuticals Announces 1-for-80 Reverse Stock Splitaccesswire.com - April 19 at 12:10 PMAvalo Therapeutics EPS of -$114.00, revenue of $1.92M beats by $0.72Mmsn.com - April 1 at 3:29 AMPieris Pharmaceuticals, Inc.: Pieris Pharmaceuticals Announces Strategy to Maximize Partnered Milestone and Royalty Potentialfinanznachrichten.de - March 28 at 2:48 PMPieris Pharmaceuticals Announces Strategy to Maximize Partnered Milestone and Royalty Potentialfinance.yahoo.com - March 27 at 8:11 AMPieris Pharmaceuticals Announces Strategy to Maximize Partnered Milestone and Royalty Potentialaccesswire.com - March 27 at 8:00 AMPIRS Apr 2024 2.500 callfinance.yahoo.com - March 19 at 8:35 PMPieris Pharmaceuticals Inc (PIRS)investing.com - February 10 at 8:42 PMPieris Pharmaceuticals, Inc. (PIRS)finance.yahoo.com - February 1 at 6:10 PMInvestors Don't See Light At End Of Pieris Pharmaceuticals, Inc.'s (NASDAQ:PIRS) Tunnel And Push Stock Down 27%finance.yahoo.com - December 18 at 7:48 AMPieris Pharmaceuticals Inc (PIRS) Earnings Dates & Reportsinvesting.com - November 20 at 1:26 PMPieris Pharmaceuticals Inc PIRSmorningstar.com - November 4 at 1:54 AMA company insider recently bought 10,000 shares of Pieris Pharmaceuticals Inc [PIRS]. Should You Buy?knoxdaily.com - October 14 at 2:06 PMPieris Pharmaceuticals Inc (PIRS) Becoming More Attractive for Investorsknoxdaily.com - October 10 at 1:11 PMDirector KIRITSY CHRISTOPHER P acquire 10,000 shares of Pieris Pharmaceuticals Inc [PIRS]knoxdaily.com - October 6 at 7:50 AMThe Attractiveness of Investing In Pieris Pharmaceuticals Inc (PIRS) is Growingknoxdaily.com - September 26 at 1:23 PMPieris Pharmaceuticals (PIRS) Upgraded to Strong Buy: Here's Whyfinance.yahoo.com - September 25 at 2:43 PMPieris Pharmaceuticals Inc. [PIRS] Director makes an insider acquire of 10,000 shares worth 8,500.knoxdaily.com - September 22 at 7:26 AMInsider Buying: KIRITSY CHRISTOPHER P, Pieris Pharmaceuticals Inc. [PIRS] Director invested 10,000 sharesknoxdaily.com - September 15 at 10:07 AMRise in PIRS’s short interest indicates Bearish sentimentknoxdaily.com - September 8 at 4:56 PMRobert W. Baird upgrades Pieris Pharmaceuticals Inc. (PIRS) rating to an Outperformknoxdaily.com - September 5 at 5:33 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsAnnexonNASDAQ:ANNXAnnexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis. The company is also developing ANX007, an antigen-binding fragment (Fab) that is in Phase 3 program for the treatment of patients with geographic atrophy; and ANX1502, a novel oral small molecule inhibitor, which is in Phase 1 clinical trials for autoimmune indications. In addition, it develops ANX009, a C1q-blocking Fab that is in Phase I clinical trial for treating patients with lupus nephritis. The company was incorporated in 2011 and is headquartered in Brisbane, California.Atossa TherapeuticsNASDAQ:ATOSAtossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing medicines in the areas of unmet medical need in oncology. The company's lead program is Endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It is also developing AT-H201 for lung injury caused by cancer treatment. In addition, the company develops immunotherapy/chimeric antigen receptor therapy programs. It has a research agreement with Dana-Farber Cancer Institute, Inc. to support research of cytokine-coated nanoparticles for the treatment of breast cancer. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is headquartered in Seattle, Washington.Nuvectis PharmaNASDAQ:NVCTNuvectis Pharma, Inc., a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. The company's lead product candidate is NXP800, a novel small molecule that is in Phase 1b clinical trials for the treatment of patients with platinum-resistant, ARID1a-mutated ovarian carcinoma. It is also developing NXP900, a small molecule drug candidate, which is in Phase 1a clinical trails that inhibits the Proto-oncogene c-Src and YES1 kinases. It has license agreement with the CRT Pioneer Fund for the NXP800 and any of related derivatives; and the University of Edinburgh for the NXP900 and any of associated derivatives. The company was formerly known as Centry Pharma, Inc. and changed its name to Nuvectis Pharma, Inc. in July 2021. Nuvectis Pharma, Inc. was incorporated in 2020 and is based in Fort Lee, New Jersey.ObsEvaNASDAQ:OBSVObsEva SA is a clinical-stage biopharmaceutical company, which engages in the research and development of therapeutic treatments for women's reproductive health and pregnancy. It offers biopharmaceutical drugs addressing conditions compromising pregnancy from conception to birth. The company was founded by Ernest Loumaye and André Chollet on November 14, 2012 and is headquartered in Geneva, Switzerland.Pieris PharmaceuticalsNASDAQ:PIRSPieris Pharmaceuticals, Inc., a biotechnology company, discovers and develops biotechnological applications. The company focuses on the development of its 4-1BB bispecifics immuno-oncology (IO) programs. Its clinical pipeline consists of IO bispecifics, including S095012 (PRS-344), a bispecific Mabcalin compound targeting PD-L1 and 4-1BB in partnership with Les Laboratoires Servier and Institut de Recherches Internationales Servier; SGN-BB228 (PRS-346), a CD228 x 4-1BB bispecific antibody-Anticalin compound targeting CD228 and 4-1BB in partnership with Pfizer Inc.; and BOS-342 (PRS-342), a GPC3 x 4-1BB bispecific Mabcalin compound targeting GPC3 and 4-1BB in partnership with Boston Pharmaceuticals, which are in phase 1 studies. The company was founded in 2001 and is headquartered in Boston, Massachusetts. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.